JP2000502141A - 低い多分散指数を有するヒアルロン酸分画の調製方法 - Google Patents
低い多分散指数を有するヒアルロン酸分画の調製方法Info
- Publication number
- JP2000502141A JP2000502141A JP09522511A JP52251197A JP2000502141A JP 2000502141 A JP2000502141 A JP 2000502141A JP 09522511 A JP09522511 A JP 09522511A JP 52251197 A JP52251197 A JP 52251197A JP 2000502141 A JP2000502141 A JP 2000502141A
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- molecular weight
- average molecular
- range
- polydispersity index
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 83
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 81
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title claims description 60
- 239000000061 acid fraction Substances 0.000 title claims description 22
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000005708 Sodium hypochlorite Substances 0.000 claims abstract description 16
- 238000002604 ultrasonography Methods 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims 1
- 108091006629 SLC13A2 Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 23
- 230000008569 process Effects 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000354 decomposition reaction Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical class Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 7
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000005227 gel permeation chromatography Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000000527 sonication Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 241000561734 Celosia cristata Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012691 depolymerization reaction Methods 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 5,000 から300,000 までの範囲の平均分子量を有するヒアルロン酸又は それの塩の分画の調製において、50,000から10,000,000までの範囲の平均分子量 を有する出発ヒアルロン酸又はその塩を、次亜塩素酸ナトリウム/ヒアルロン酸 繰返し単位のモル比が0.01と5 の間より成るような濃度での次亜塩素酸ナトリウ ムの存在下で同時に超音波で240分以下の時間処理することより成る調製方法。 2. ヒアルロン酸が100,000 と1,500,000 の範囲の分子量を有する鶏頭から 抽出される、請求項1に記載の方法。 3. 生成するヒアルロン酸分画が5,000から50,000までの範囲の分子量を持 つ、請求項2に記載の方法。 4. 生成するヒアルロン酸分画が5,000〜10,000の範囲の平均分子量を持つ 、請求項3に記載の方法。 5. 生成するヒアルロン酸が10,000〜15,000の範囲の平均分子量を持つ、請 求項3に記載の方法。 6. 生成するヒアルロン酸が15,000〜25,000の範囲の平均分子量を持つ、請 求項3に記載の方法。 7. 25,000〜50,000の範囲の平均分子量を持つ請求項3に記載の方法。 8. 出発ヒアルロン酸が発酵工程からの由来であり且つ1,000,000 から5,00 0,000 までの範囲の平均分子量を有する、請求項1に記載の方法。 9. 生成するヒアルロン酸分画が50,000から300,000 までの範囲の平均分子 量を持つ、請求項8に記載の方法。 10. 出発ヒアルロン酸が生体外合成からの由来であり且つ50,000から10,0 00,000までの範囲の平均分子量を有する、請求項2に記載の方法。 11. 出発ヒアルロン酸又はそれの塩を含むNaC1水溶液が温度4℃且つ濃度1 0mg/mlで実行される、請求項1-10の何れにも記載の方法。 12. 1から20重量%の範囲の濃度を有する水溶液の形でNaC10が前記溶液 に添加される、請求項11に記載の方法。 13. モル比 NaClO/ヒアルロン酸繰返し単位が0.5 と2.5 の間より成るよ うな濃度でNaClO が添加される、請求項1-12の何れにも記載の方法。 14. 120 と240 分の間より成る時間実行される、請求項1-13の何れに も記載の方法。 15. 超音波が50と200Wの間より成る出力を有する、請求項1−14の何れ にも記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT95PD000244A IT1282219B1 (it) | 1995-12-20 | 1995-12-20 | Processo chimico fisico combinato per la preparazione di frazioni di acido ialuronico a basso peso molecolare caratterizzate da bassa |
IT95A000244 | 1995-12-20 | ||
PCT/EP1996/005701 WO1997022629A1 (en) | 1995-12-20 | 1996-12-19 | A process for preparing a hyaluronic acid fraction having a low polydispersion index |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000502141A true JP2000502141A (ja) | 2000-02-22 |
JP4094059B2 JP4094059B2 (ja) | 2008-06-04 |
Family
ID=11391198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52251197A Expired - Fee Related JP4094059B2 (ja) | 1995-12-20 | 1996-12-19 | 低い多分散指数を有するヒアルロン酸分画の調整方法 |
Country Status (14)
Country | Link |
---|---|
US (2) | US6020484A (ja) |
EP (1) | EP0868437B1 (ja) |
JP (1) | JP4094059B2 (ja) |
AT (1) | ATE184024T1 (ja) |
AU (1) | AU703332B2 (ja) |
CZ (1) | CZ291394B6 (ja) |
DE (1) | DE69604087T2 (ja) |
DK (1) | DK0868437T3 (ja) |
ES (1) | ES2139402T3 (ja) |
GR (1) | GR3031973T3 (ja) |
HU (1) | HU226949B1 (ja) |
IL (1) | IL124909A (ja) |
IT (1) | IT1282219B1 (ja) |
WO (1) | WO1997022629A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006101030A1 (ja) * | 2005-03-22 | 2006-09-28 | Q.P. Corporation | 低分子ヒアルロン酸および/またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物 |
WO2007099830A1 (ja) * | 2006-02-24 | 2007-09-07 | Q.P. Corporation | 新規な低分子ヒアルロン酸および/またはその塩、ならびにこれを用いた化粧料、医薬組成物および食品組成物 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1282219B1 (it) * | 1995-12-20 | 1998-03-16 | Fidia Advanced Biopolymers Srl | Processo chimico fisico combinato per la preparazione di frazioni di acido ialuronico a basso peso molecolare caratterizzate da bassa |
IT1291452B1 (it) | 1997-04-14 | 1999-01-11 | Fidia Advanced Biopolymers Srl | Rivestimento a base di acido ialuronico e suoi derivati per la protezione di parti elettroniche da agenti esterni |
US20020172712A1 (en) * | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
US20060153893A1 (en) * | 2002-04-08 | 2006-07-13 | Denki Kagaku Kogyo Kabushiki Kaisha | Therapeutic composition for bone infectious disease |
US20050142208A1 (en) * | 2002-05-09 | 2005-06-30 | Won Min Yoo | Pharmceutical composition for treatment of wounds conntaining blood plasma or serum |
AU2003228958C1 (en) * | 2002-05-17 | 2009-01-08 | Fidia Advanced Biopolymers, S.R.L. | Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins |
AU2003247816A1 (en) * | 2002-07-02 | 2004-01-23 | Procyte Corporation | Compositions containing peptide copper complexes and soft tissue fillers |
US20060183709A1 (en) * | 2005-02-15 | 2006-08-17 | Ahmad Alkayali | Preparation of low molecular weight hyaluronic acid as a food supplement |
US7323184B2 (en) * | 2005-08-22 | 2008-01-29 | Healagenics, Inc. | Compositions and methods for the treatment of wounds and the reduction of scar formation |
WO2008000260A1 (en) * | 2006-06-28 | 2008-01-03 | Novozymes Biopolymer A/S | Compositions with several hyaluronic acid fractions for cosmetic and medical uses |
WO2008003321A2 (en) * | 2006-07-07 | 2008-01-10 | Novozymes Biopolymer A/S | Compositions with several hyaluronic acid fractions for cosmetic use |
JP2009545637A (ja) | 2006-08-04 | 2009-12-24 | ノボザイムス バイオファーマ デーコー アクティーゼルスカブ | 分岐ヒアルロン酸及びその製造方法 |
US8529951B1 (en) | 2007-02-21 | 2013-09-10 | Anand Ramamurthi | Elastogenic cues and methods for using same |
KR20100094982A (ko) | 2007-11-13 | 2010-08-27 | 바이오-테크널러지 제너럴 (이스라엘) 리미티드 | 점탄성 바이오폴리머의 희석식 여과 멸균 방법 |
US20130209531A1 (en) * | 2010-06-08 | 2013-08-15 | University Of Utah Research Foundation | Applications of partially and fully sulfated hyaluronan |
CN113512134B (zh) * | 2021-07-30 | 2022-05-20 | 梅晔生物医药股份有限公司 | 一种全分子量分布的透明质酸钠及其制备方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
NO169637C (no) * | 1983-10-11 | 1992-07-22 | Fidia Spa | Fremgangsmaate for fremstilling av terapeutisk aktive hyaluronsyre-fraksjoner |
US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
GB8713747D0 (en) * | 1987-06-12 | 1987-07-15 | Unilever Plc | Skin treatment composition |
IT1219587B (it) * | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | Polisaccaridi carbossiilici autoreticolati |
JPH0675512B2 (ja) * | 1989-03-20 | 1994-09-28 | 株式会社紀文食品 | 低重合度ヒアルロン酸アルカリ塩の製造方法 |
IT1247175B (it) * | 1991-04-19 | 1994-12-12 | Fidia Spa | Procedimento per la purificazione di acido ialuronico e frazione di acido ialuronico puro per uso oftalmico. |
IT1260148B (it) * | 1992-04-17 | 1996-03-28 | Fidia Spa | Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo |
IT1268954B1 (it) * | 1994-03-11 | 1997-03-18 | Fidia Advanced Biopolymers Srl | Processo per la preparazione di acido ialuronico mediante sintesienzimatica e relative composizioni farmaceutiche |
ITPD940054A1 (it) * | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
IT1282219B1 (it) * | 1995-12-20 | 1998-03-16 | Fidia Advanced Biopolymers Srl | Processo chimico fisico combinato per la preparazione di frazioni di acido ialuronico a basso peso molecolare caratterizzate da bassa |
-
1995
- 1995-12-20 IT IT95PD000244A patent/IT1282219B1/it active IP Right Grant
-
1996
- 1996-12-19 WO PCT/EP1996/005701 patent/WO1997022629A1/en active IP Right Grant
- 1996-12-19 AT AT96944007T patent/ATE184024T1/de active
- 1996-12-19 US US09/096,646 patent/US6020484A/en not_active Expired - Lifetime
- 1996-12-19 AU AU13749/97A patent/AU703332B2/en not_active Ceased
- 1996-12-19 DK DK96944007T patent/DK0868437T3/da active
- 1996-12-19 HU HU9903666A patent/HU226949B1/hu not_active IP Right Cessation
- 1996-12-19 EP EP96944007A patent/EP0868437B1/en not_active Expired - Lifetime
- 1996-12-19 DE DE69604087T patent/DE69604087T2/de not_active Expired - Lifetime
- 1996-12-19 CZ CZ19981889A patent/CZ291394B6/cs not_active IP Right Cessation
- 1996-12-19 ES ES96944007T patent/ES2139402T3/es not_active Expired - Lifetime
- 1996-12-19 IL IL12490996A patent/IL124909A/en not_active IP Right Cessation
- 1996-12-19 JP JP52251197A patent/JP4094059B2/ja not_active Expired - Fee Related
-
1999
- 1999-10-26 US US09/426,536 patent/US6232303B1/en not_active Expired - Lifetime
- 1999-11-29 GR GR990403066T patent/GR3031973T3/el unknown
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006101030A1 (ja) * | 2005-03-22 | 2006-09-28 | Q.P. Corporation | 低分子ヒアルロン酸および/またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物 |
JP2006265287A (ja) * | 2005-03-22 | 2006-10-05 | Q P Corp | 低分子ヒアルロン酸および/またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物 |
JP4576583B2 (ja) * | 2005-03-22 | 2010-11-10 | キユーピー株式会社 | ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物 |
US8933054B2 (en) | 2005-03-22 | 2015-01-13 | Q.P. Corporation | Low molecular weight hyaluronic acid and/or salt thereof, method for producing same, and cosmetic preparation and food composition containing same |
WO2007099830A1 (ja) * | 2006-02-24 | 2007-09-07 | Q.P. Corporation | 新規な低分子ヒアルロン酸および/またはその塩、ならびにこれを用いた化粧料、医薬組成物および食品組成物 |
US8367818B2 (en) | 2006-02-24 | 2013-02-05 | Q.P. Corporation | Low molecular weight hyaluronic acid and/or salt thereof, and cosmetic preparation, pharmaceutical composition, and food composition each using same |
JP5289936B2 (ja) * | 2006-02-24 | 2013-09-11 | キユーピー株式会社 | 新規な低分子ヒアルロン酸および/またはその塩、ならびにこれを用いた化粧料、医薬組成物および食品組成物 |
Also Published As
Publication number | Publication date |
---|---|
HUP9903666A2 (hu) | 2000-03-28 |
IL124909A0 (en) | 1999-01-26 |
DE69604087T2 (de) | 2000-02-24 |
IL124909A (en) | 2002-09-12 |
WO1997022629A1 (en) | 1997-06-26 |
US6232303B1 (en) | 2001-05-15 |
DE69604087D1 (de) | 1999-10-07 |
CZ188998A3 (cs) | 1998-09-16 |
ES2139402T3 (es) | 2000-02-01 |
ATE184024T1 (de) | 1999-09-15 |
AU703332B2 (en) | 1999-03-25 |
HU226949B1 (en) | 2010-03-29 |
ITPD950244A0 (ja) | 1995-12-20 |
JP4094059B2 (ja) | 2008-06-04 |
GR3031973T3 (en) | 2000-03-31 |
ITPD950244A1 (it) | 1997-06-20 |
CZ291394B6 (cs) | 2003-02-12 |
DK0868437T3 (da) | 2000-03-13 |
AU1374997A (en) | 1997-07-14 |
US6020484A (en) | 2000-02-01 |
IT1282219B1 (it) | 1998-03-16 |
EP0868437B1 (en) | 1999-09-01 |
HUP9903666A3 (en) | 2001-03-28 |
EP0868437A1 (en) | 1998-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Bioactive polysaccharides from natural resources including Chinese medicinal herbs on tissue repair | |
JP2000502141A (ja) | 低い多分散指数を有するヒアルロン酸分画の調製方法 | |
EP0340628B1 (en) | Sulfoamino derivatives of chondroitin sulfates, of dermaten sulfate and of hyaluronic acid and their pharmacological properties | |
DK173818B1 (da) | Heparinderivat | |
JP4278716B2 (ja) | N−硫酸化ヒアルロン酸化合物、その誘導体および製造方法 | |
CN101501075B (zh) | 支化透明质酸和制造方法 | |
JP2004507586A (ja) | 過カルボン酸エステル化された多糖類、及びそれらの作製方法 | |
KR20010101001A (ko) | 교차 결합된 히알루론산과 그것의 의학적 용도 | |
EP1117695A1 (fr) | Polymeres biocompatibles, leur procede de preparation et les compositions les contenant | |
CA2285383C (en) | Glycosaminoglycans having high antithrombotic activity | |
JP2009516765A (ja) | 新規ヒアルロン酸誘導体、その製造方法及びその使用 | |
IL205968A (en) | Botry Esters - Mixed Forms of Acidic Polysaccharides, Preparation and Cosmetics for Skin Containing Them | |
Muntimadugu et al. | Polysaccharide biomaterials | |
US20160067275A1 (en) | Co-crosslinked phosphated native and/or functionalized polysaccharide-based hydogel | |
AU2002236118B2 (en) | Highly sulfated derivatives of K5 polysaccharide and their preparation | |
JP2001163789A (ja) | マトリックスメタロプロテアーゼ阻害用医薬組成物 | |
JP4958368B2 (ja) | 架橋ヒアルロン酸 | |
CA2240682C (en) | A process for preparing a hyaluronic acid fraction having a low polydispersion index | |
RU2639574C2 (ru) | Способ получения низкомолекулярного гепарина | |
WO2008090583A1 (en) | Phosphated derivatives of polysaccharides and uses thereof | |
EP3922268B1 (en) | New derivatives obtained from hyaluronic acid and carnosine | |
IL141230A (en) | Hyaluronic acid derivatives obtained from hyaluronic acid fraction having a low polydispersion index and pharmaceutical compositions and healthcare products containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20031127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070626 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070926 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071025 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071207 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080121 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080305 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110314 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110314 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |